Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
STRATA Skin Sciences Inc (SSKN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SSKN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -12.27% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.22M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 3394 | Beta 1.33 | 52 Weeks Range 2.51 - 5.90 | Updated Date 04/1/2025 |
52 Weeks Range 2.51 - 5.90 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.6 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-25 | When Before Market | Estimate -0.4 | Actual 0.2872 |
Profitability
Profit Margin -28.72% | Operating Margin (TTM) -18.79% |
Management Effectiveness
Return on Assets (TTM) -8.85% | Return on Equity (TTM) -73.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20426865 | Price to Sales(TTM) 0.34 |
Enterprise Value 20426865 | Price to Sales(TTM) 0.34 | ||
Enterprise Value to Revenue 0.63 | Enterprise Value to EBITDA -7008.83 | Shares Outstanding 4171160 | Shares Floating 1578034 |
Shares Outstanding 4171160 | Shares Floating 1578034 | ||
Percent Insiders 2.91 | Percent Institutions 63.8 |
Analyst Ratings
Rating 5 | Target Price 16 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
STRATA Skin Sciences Inc
Company Overview
History and Background
STRATA Skin Sciences, formerly MELA Sciences, was founded to develop and commercialize products for the detection and treatment of dermatologic conditions. It focuses on medical technologies for dermatology.
Core Business Areas
- XTRAC Laser System: This segment involves the sale and rental of the XTRAC excimer laser system, used for the treatment of psoriasis, vitiligo, and atopic dermatitis.
- Pharos Laser System: Similar to XTRAC, Pharos is another excimer laser system offered for dermatological treatments.
- STRATA Skin Care Products: This segment includes the sale of skincare products intended to complement the laser treatments and manage dermatological conditions.
Leadership and Structure
Danya Bostrom is the CEO. The organizational structure includes departments for sales, marketing, research and development, and operations.
Top Products and Market Share
Key Offerings
- XTRAC Laser: The XTRAC laser system is a key revenue driver. Market share data specific to XTRAC is difficult to obtain, but it's a significant player in the excimer laser market. Competitors include Ra Medical Systems (now defunct).
- Pharos Laser: The Pharos laser system competes with XTRAC in the same therapeutic areas. Market share data specific to Pharos is difficult to obtain, but the laser contributes to their revenue.
Market Dynamics
Industry Overview
The dermatology device market is growing, driven by increasing prevalence of skin conditions and demand for non-invasive treatments.
Positioning
STRATA Skin Sciences is positioned as a provider of light-based therapies for dermatological conditions.
Total Addressable Market (TAM)
The global dermatology devices market is projected to reach billions of dollars. STRATA's TAM is within the excimer laser therapy segment, which is a subset of the broader dermatology devices market. They are positioned to grow as light-based treatments become more prevalent.
Upturn SWOT Analysis
Strengths
- Established product portfolio in light-based dermatology
- Strong brand recognition in the XTRAC laser market
- Proprietary technology
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on a small number of key products
- History of inconsistent profitability
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing laser technologies
- Acquiring complementary technologies or products
Threats
- Competition from established medical device companies
- Technological advancements rendering current products obsolete
- Changes in reimbursement policies for dermatological treatments
Competitors and Market Share
Key Competitors
- LMTX
Competitive Landscape
STRATA competes with companies that focus on light-based therapies. STRATA's advantage lies in its XTRAC laser, but it faces challenges from larger competitors with greater resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent, with periods of rapid growth followed by periods of stagnation.
Future Projections: Future growth projections are dependent on successful execution of strategic initiatives and market conditions. Analysts estimate continued revenue growth
Recent Initiatives: Recent strategic initiatives include focusing on product improvements and sales force effectiveness.
Summary
STRATA Skin Sciences has an established presence in the light-based dermatology market with key products like XTRAC. However, the company's inconsistent profitability and reliance on a small number of products present challenges. Opportunities for growth exist through geographic expansion and new applications, but competition and technological advancements pose threats. The company needs to achieve more consistent financial performance and demonstrate sustainable growth to improve its overall strength.
Similar Companies
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is based on available information and is subject to change. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About STRATA Skin Sciences Inc
Exchange NASDAQ | Headquaters Horsham, PA, United States | ||
IPO Launch date 2005-10-28 | President, CEO & Vice-Chairman Dr. Dolev Rafaeli Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 99 | |
Full time employees 99 | |||
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.